Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFINE: Rituximab in Generalized Myasthenia Gravis
NCT05868837Phase 3Recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2022
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Rituximab with Placebo (2 arms). Primary endpoint: Quantitative Myasthenia Gravis Score at 12 weeks. Started Feb 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05868837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868837.